ISTA Pharmaceuticals

ISTA Pharmaceuticals was an American pharmaceutical company specializing in products for ophthalmic diseases. ISTA Pharmaceuticals was acquired by Bausch Health in 2012.

History

ISTA Pharmaceuticals was founded in 1992. The company was initially focused on developing and marketing products in the areas of allergy, inflammation, and ophthalmology. In 2000, ISTA Pharmaceuticals went public, trading on the NASDAQ stock exchange.

In 2012, ISTA Pharmaceuticals was acquired by Bausch Health (formerly known as Valeant Pharmaceuticals). The acquisition was part of Bausch Health's strategy to expand its portfolio of ophthalmology products.

Products

ISTA Pharmaceuticals developed several notable products during its operation. These include:

• Bromday: A once-daily nonsteroidal anti-inflammatory drug (NSAID) for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
• Xibrom: An ophthalmic solution for the treatment of ocular pain and inflammation following cataract surgery.
• Istalol: A beta-adrenergic receptor blocking agent for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Acquisition by Bausch Health

In 2012, ISTA Pharmaceuticals was acquired by Bausch Health for approximately $500 million. The acquisition expanded Bausch Health's portfolio of ophthalmology products and strengthened its position in the global eye health market.

See also

• Bausch Health
• Pharmaceutical industry in the United States
• List of pharmaceutical companies

References

   This article is a United States corporation or company stub. You can help WikiMD by expanding it!

   This article is a pharmacology-related stub. You can help WikiMD by expanding it!